Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 30 points (0.2%) at 15,994 as of Thursday, Feb. 13, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,823 issues advancing vs. 1,044 declining with 196 unchanged. The Drugs industry currently sits up 0.3% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Pacira Pharmaceuticals ( PCRX), up 11.3%, Celgene Corporation ( CELG), up 2.0%, AstraZeneca ( AZN), up 1.6%, Biogen Idec ( BIIB), up 0.8% and Allergan ( AGN), up 0.8%. A company within the industry that fell today was Regeneron Pharmaceuticals ( REGN), up 0.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Valeant Pharmaceuticals International ( VRX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Valeant Pharmaceuticals International is up $0.80 (0.6%) to $141.57 on average volume. Thus far, 573,541 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $140.00-$141.74 after having opened the day at $140.53 as compared to the previous trading day's close of $140.77. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $47.1 billion and is part of the health care sector. Shares are up 19.9% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.